Dr. Rebecca Suk Heist, MD, MPH

Dr. Heist practices at Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Heist's NPI, 1184697278, was assigned on February 9, 2006. Dr. Heist graduated from Harvard Medical School in 1999. Dr. Heist holds Massachusetts license 212736.

Dr. Heist's primary practice is Massachusetts General Hospital, at 55 Fruit Street, Boston, MA 02114 in Suffolk County. The practice phone is (617) 726-2000.

Dr. Heist's primary practice is Massachusetts General Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Heist is also affiliated with Brigham and Women's Hospital. The medical group on file is Massachusetts General Hospital. Dmand AI also links Dr. Heist to 3 more hospitals, 3 group practices and clinics, 2 medical groups, 1 community health center and 1 home health agency, each named with a free account. Dr. Heist's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Heist practices, 10 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Heist's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Heist is board certified in medical oncology by the American Board of Internal Medicine. Dr. Heist is licensed in Massachusetts.

Dmand AI lists colorectal cancer, deep vein thrombosis (DVT), lung cancer and prostate cancer among the conditions Dr. Heist treats.

CMS data shows 468 Medicare services from Dr. Heist across 3 procedure codes in 2024, for 115 Medicare patients. Medicare paid $32,956 for them.

CMS counts 115 Medicare patients who saw Dr. Heist in 2024. The largest group is 75 to 84, with 52 patients. 75% of them have cancer, and 75% have high blood pressure. 17% are also on Medicaid. Their average risk score is 2.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Heist's median patient age at 76, with 65% women.

In 2024, Dr. Heist wrote 174 Medicare Part D claims for 38 patients. 68% of them were for generic drugs. CMS names the drug for 61 of them, across 3 drugs with 11 or more claims each, at $236,726 in total drug cost. In 2023, CMS named 22 claims across 1 drug.

Dr. Heist accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Heist as offering telehealth.

Dmand AI links 191 papers to Dr. Heist, published from 2006 to 2025. 2018 was the busiest year, with 14. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Adenocarcinoma. Dr. Heist has published most often in Clin Cancer Res. Dr. Heist's most frequent co-authors are Lecia V. Sequist, MD, Subba R. Digumarthy, MD and Zofia Piotrowska, MD.

Dmand AI links Dr. Heist to 24 clinical trials, 9 of them phase 1 studies. 6 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung and Adenocarcinoma of Lung. Dana-Farber Cancer Institute sponsors the most, 4. Open Payments lists research payments to Dr. Heist that name 2 trials.

CMS Open Payments shows 126 general payments to Dr. Heist from 17 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Novartis Pharmaceuticals Corporation paid the most, $33,047. It also lists 6 research payments totaling $74,221 from 2016 to 2025, naming 2 clinical trials.

Dr. Heist graduated from Harvard Medical School in 1999. Dr. Heist is a member of ASCO.

Dr. Heist is in network with 11 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 9. Check the plan with the practice before a visit.